Form SC 13G - Statement of Beneficial Ownership by Certain Investors

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )*

 

 

CIDARA THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE PER SHARE

(Title of Class of Securities)

171757 20 6

(CUSIP Number)

July 18, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

---

CUSIP No. 171757 20 6		SCHEDULE 13G		Page 2 of 7 Pages

 

1.		NAMES OF REPORTING PERSONS    Canaan XII L.P.
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a) ☐  (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION    Cayman Islands

NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER    1,400,000(1)
				6.		SHARED VOTING POWER    0
				7.		SOLE DISPOSITIVE POWER    1,400,000(1)
				8.		SHARED DISPOSITIVE POWER    0

9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    1,400,000(1)
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9     9.99%(2)
12.		TYPE OF REPORTING PERSON    PN

 

(1)

Consists of (i) 703,080 shares of common stock, $0.0001 par value per share, (“Common Stock”) of the Issuer directly held by Canaan XII L.P., a Cayman Islands limited partnership (the “Fund”), and 696,920 shares of Common Stock issuable upon the conversion of Series A preferred stock (“Series A Preferred Stock”) directly held by the Fund. The Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock (“Certificate of Designation”) provides that a holder of Series A Preferred Stock generally has the right to convert each share of Series A Preferred Stock into 70 shares of Common Stock, provided that, subject to certain exceptions, a holder will not have a right to convert Series A Preferred Stock into Common Stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion. Accordingly, the Fund’s ability to convert Series A Preferred Stock (and its resulting beneficial ownership) currently is limited by this conversion blocker.

(2)	The percent of class was calculated based on 7,038,241 shares of Common Stock outstanding as of July 19, 2024, as disclosed in the Form S-1 Registration Statement as filed by the Issuer with the Securities and Exchange Commission (“SEC”) on July 19, 2024.

---

CUSIP No. 171757 20 6		SCHEDULE 13G		Page 3 of 7 Pages

 

1.		NAMES OF REPORTING PERSONS    Canaan Partners XII LLC
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a) ☐  (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION     Delaware

NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER    1,400,000(1)
				6.		SHARED VOTING POWER    0
				7.		SOLE DISPOSITIVE POWER    1,400,000(1)
				8.		SHARED DISPOSITIVE POWER    0

9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    1,400,000(1)
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9    9.99%(2)
12.		TYPE OF REPORTING PERSON    OO

 

(1)

Consists of (i) 703,080 shares of Common Stock of the Issuer directly held by the Fund, and 696,920 shares of Common Stock issuable upon the conversion of Series A Preferred Stock directly held by the Fund. The Certificate of Designation provides that a holder of Series A Preferred Stock generally has the right to convert each share of Series A Preferred Stock into 70 shares of Common Stock, provided that, subject to certain exceptions, a holder will not have a right to convert Series A Preferred Stock into Common Stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion. Accordingly, the Fund’s ability to convert Series A Preferred Stock (and its resulting beneficial ownership) currently is limited by this conversion blocker. Canaan Partners XII LLC, a Delaware limited liability company (the “General Partner”) is the general partner of the Fund and may be deemed to beneficially own the shares held by the Fund.

(2)	The percent of class was calculated based on 7,038,241 shares of Common Stock outstanding as of July 19, 2024, as disclosed in the Form S-1 Registration Statement as filed by the Issuer with the SEC on July 19, 2024.

---

CUSIP No. 171757 20 6		SCHEDULE 13G		Page 4 of 7 Pages

 

Item 1.   Issuer
			(a)			Name of Issuer:
						Cidara Therapeutics, Inc.
			(b)			Address of Issuer’s Principal Executive Offices:
						6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121
Item 2.   Filing Person
			(a) –(c) Name of Persons Filing; Address; Citizenship:
						(i) Canaan XII L.P., a Cayman Islands limited partnership; and   (ii) Canaan Partners XII LLC, a Delaware limited liability company.   The address of the principal business office of each of the reporting persons is 2765 Sand Hill Road, Menlo Park, California 94025.
			(d)			Title of Class of Securities:
						Common Stock, $0.0001 par value per share
			(e)			CUSIP Number: 171757 20 6
Item 3.   If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
			(a)			☐		Broker or dealer registered under Section 15 of the Act;
			(b)			☐		Bank as defined in Section 3(a)(6) of the Act;
			(c)			☐		Insurance company as defined in Section 3(a)(19) of the Act;
			(d)			☐		Investment company registered under Section 8 of the Investment Company Act of 1940;
			(e)			☐		An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
			(f)			☐		An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
			(g)			☐		A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
			(h)			☐		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
			(i)			☐		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
			(j)			☐		A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
			(k)			☐		Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
			If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

---

CUSIP No. 171757 20 6		SCHEDULE 13G		Page 5 of 7 Pages

 

Item 4.

Ownership.

 

(a)	and (b) Amount beneficially owned:

 

(i)	The Fund directly owns 1,400,000(1) shares of Common Stock, which represents approximately 9.99%(2) of the outstanding shares of Common Stock.

 

(ii)	The General Partner is the general partner of the Fund and may be deemed to beneficially own 1,400,000 shares of Common Stock, which represents approximately 9.99%(2) of the outstanding shares of Common Stock.

 

(c)	Number of shares as to which such person has:

 

		Number of Shares of Common Stock
Reporting Person		(i)				(ii)				(iii)				(iv)
Canaan XII L.P.			1,400,000	(1)			0				1,400,000	(1)			0
Canaan Partners XII LLC			1,400,000	(1)			0				1,400,000	(1)			0

 

(i)	Sole power to vote or direct the vote

 

(ii)	Shared power to vote or to direct the vote

 

(iii)

Sole power to dispose or to direct the disposition of

 

(iv)	Shared power to dispose or to direct the disposition of

 

(1)

Consists of (i) 703,080 shares of Common Stock of the Issuer directly held by the Fund, and 696,920 shares of Common Stock issuable upon the conversion of Series A Preferred Stock directly held by the Fund. The Certificate of Designation provides that a holder of Series A Preferred Stock generally has the right to convert each share of Series A Preferred Stock into 70 shares of Common Stock, provided that, subject to certain exceptions, a holder will not have a right to convert Series A Preferred Stock into Common Stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion. Accordingly, the Fund’s ability to convert Series A Preferred Stock (and its resulting beneficial ownership) currently is limited by this conversion blocker. The General Partner is the general partner of the Fund and may be deemed to beneficially own the shares held by the Fund.

 

(2)	The percent of class was calculated based on 7,038,241 shares of Common Stock outstanding as of July 19, 2024, as disclosed in the Form S-1 Registration Statement as filed by the Issuer with the Securities and Exchange Commission on July 19, 2024.

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

---

CUSIP No. 171757 20 6		SCHEDULE 13G		Page 6 of 7 Pages

 

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

Not applicable.

 

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

---

CUSIP No. 171757 20 6		SCHEDULE 13G		Page 7 of 7 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 29, 2024

 

CANAAN XII L.P.
By:		CANAAN PARTNERS XII LLC, its General Partner
By:		/s/ Nancy Levenson
		Nancy Levenson, Attorney-in-Fact
CANAAN PARTNERS XII LLC
By:		/s/ Nancy Levenson
		Nancy Levenson, Attorney-in-Fact

Exhibit 24

POWER OF ATTORNEY

1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the signature pages hereto (such date, for each Grantor, is hereinafter referred to as such Grantor’s “Effective Date”), hereby constitutes and appoints each of the employees, partners or managers of Canaan Management LLC (together with its subsidiaries and affiliates, “Canaan Partners”) listed on Schedule A attached hereto, which schedule may be amended from time to time by the Chief Financial Officer or Chief Operating Officer of Canaan Partners to remove any such employee, manager or partner or to add any new employee, partner or manager of Canaan Partners (each such employee, partner or manager, an “Attorney-In-Fact”) as the Grantor’s true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the Grantor and in the Grantor’s place and stead, in any and all capacities to: (a) sign any and all instruments, certificates and documents required to be executed on behalf of the Grantor as an individual (if applicable) or in the Grantor’s capacity as a general partner, manager, member, managing member or authorized signatory, as the case may be, on behalf of any of the following (i) Canaan Partners, (ii) any of the funds or accounts managed, advised or sponsored by Canaan Partners (the “Canaan Funds”) and (iii) any of the entities formed to act as the direct or indirect general partner, manager, managing member or equivalent of such funds or accounts (the “Canaan General Partners”, together with Canaan Partners and the Canaan Funds collectively, the “Canaan Entities”), in each case, pursuant to the Securities Act of 1933, as amended, (the “Securities Act”), and any and all rules and regulations promulgated thereunder (including, without limitation, filings pursuant to Rule 144 (Form 144)) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all rules and regulations promulgated thereunder (including, without limitation, filings pursuant to Section 16 (Forms 3, 4 and 5) and Section 13 (Schedule 13D, Schedule 13G, Form 13F and Form 13H) of the Exchange Act); and (b) file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Securities Act, the Exchange Act or by the Financial Industry Regulatory Authority, granting unto such Attorney-In-Fact full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as the Grantor might or could do in person thereby, and ratifying and confirming all that such Attorney-In-Fact, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof, or may have done in connection with the matters described above. By this power of attorney, each Grantor hereby revokes all previous powers of attorney granted by him, her or it to any Attorney-In-Fact or any other employee, representative or agent of Canaan Partners relating to the matters described above.

2. Effective Date and Termination. This power of attorney shall be effective as to each Grantor as of such Grantor’s Effective Date and shall remain in full force and effect with respect to each Grantor and each Attorney-In-Fact until:

(a) in the case of any Grantor that is an individual, the earlier of the date on which this power of attorney is revoked in writing by such Grantor solely as it relates to himself or herself and such Grantor’s Termination Date (as defined below);

(b) in the case of any Grantor that is an entity, the earlier of the date on which this power of attorney is revoked in writing by such Grantor solely as it relates to itself and the filing by such entity of a certificate of cancellation or notice of dissolution with the jurisdiction in which it was organized evidencing such entity’s complete dissolution and termination under the laws of such jurisdiction; and

(c) in the case of any Attorney-In-Fact, the earlier of the date on which such person is no longer listed on Schedule A attached hereto as an “Attorney-In-Fact” or such Attorney-In-Fact’s Termination Date.

For purposes of the foregoing, “Termination Date” means (i) with respect to any Grantor or Attorney-In-Fact that is a member or manager of any Canaan General Partner, the date on which such Grantor becomes a “retired member” of any Canaan General Partner or, if later, the date on which his, her or its employment with Canaan Partners terminates for any reason and (ii) with respect to any other Grantor or Attorney-In-Fact, the date on which his, her or its employment with Canaan Partners terminates for any reason.

---

3. Miscellaneous. Each of the Grantors may execute this power of attorney in separate counterparts, and each counterpart shall be deemed to be an original instrument. This Agreement shall be governed by the laws of the State of Delaware, without regard for choice-of-law provisions.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

---

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the respective dates set forth below.

 

Dated: July 29, 2024				Canaan XII L.P.
				By: Canaan Partners XII LLC, its General Partner
				By:		/s/ John J. Pacifico III
				Name:		John J. Pacifico III
				Title:		Member/Manager
Dated: July 29, 2024				Canaan Partners XII LLC
				By:		/s/ John J. Pacifico III
				Name:		John J. Pacifico III
				Title:		Member/Manager

[Signature page to Power of Attorney]

---

Schedule A

Guy M. Russo

Nancy Levenson

Janine MacDonald

John J. Pacifico III

EXHIBIT 99.1

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: July 29, 2024

 

CANAAN XII L.P.
By:		CANAAN PARTNERS XII LLC, its General Partner
By:		/s/ Nancy Levenson
		Nancy Levenson, Attorney-in-Fact
CANAAN PARTNERS XII LLC
By:		/s/ Nancy Levenson
		Nancy Levenson, Attorney-in-Fact

 

---